Using Machine Learning for Drug Discovery in IBD

Sarah Kidwai, David Rojas-Velazquez, Dora Kožinec, Lukas Vaišvilas, Paula Perez-Pardo, Alejandro Lopez-Rincon

Research output: Chapter in Book/Report/Conference proceedingConference contributionAcademicpeer-review

Abstract

Inflammatory Bowel Disease (IBD) refers to two conditions: ulcerative colitis (UC) and Crohn disease (CD) [1]. IBD has a range of clinical symptoms including abdominal pain, diarrhoea, weight loss, constipation, and fatigue [2]. The main cause of IBD is unknown, but it is the result of a weakened immune system. The possible causes of IBD involve genetic and environmental factors. Unfortunately, with conventional diagnostic methods it is hard to predict therapeutic responsiveness of patients beforehand [3]. Genetic expression may be a valuable prediction tool to determine patient’ responsiveness to treatment.
Original languageEnglish
Title of host publicationCMBBE 2023 - 18th International Symposium on Computer Methods in Biomechanics and Biomedical Engineering (CMBBE 2023)
Place of PublicationParis, France
PublisherHAL open science
Pages1-2
Number of pages2
Publication statusPublished - 1 May 2023

Fingerprint

Dive into the research topics of 'Using Machine Learning for Drug Discovery in IBD'. Together they form a unique fingerprint.

Cite this